MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights • Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period • Core bus
Related Questions
Will the record double‑digit revenue growth be driven by new product launches, existing product volume, or pricing changes?
Are there any disclosed regulatory or reimbursement hurdles that could impact the scalability of the subcutaneous infusion solutions?
What macro or health‑system trends could sustain or threaten the continued double‑digit revenue growth trajectory beyond 2025?
How will the 21% year‑over‑year revenue increase affect analyst earnings estimates and target price models?
How does the Q2 performance influence the outlook for KORU Medical's pipeline candidates slated for FDA approval in 2025‑2026?
What is the expected impact of the raised guidance on institutional and retail demand for KRMD shares?
How do KORU Medical's Q2 margins and operating expenses line up with those of its primary competitors in subcutaneous infusion technology?
What is the cash conversion cycle for the increased sales and does the company have sufficient liquidity to fund its growth and R&D pipeline?
Does the company’s increased revenue translate into higher effective earnings per share (EPS) or is it offset by higher R&D or SG&A costs?
What is the revised 2025 revenue guidance and how does it compare to prior consensus forecasts?